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Positron Emission Tomography (PET) is a powerful and non-invasive imaging 
technique used for human and animal organ imaging.  Currently, the market for PET is 
project to reach $5.4 billion per year by 2015.
5
  This research focuses on the direct  
incorporation of [18F]-fluoride into PET ligands.  The widespread use of PET imaging is 
currently frustrated, in part, by the lack of efficient fluorination chemistry. 
Glutamate, one of the 20 most abundant naturally occurring amino acids, serves 
as a neurotransmitter in the central nervous system.  Glutamate functions in this capacity 
by binding to ionotropic and metabotropic receptors.  Metabotropic receptors are G-
coupled proteins that are involved in many disorders such as Parkinson’s disease, anxiety, 
depression and addiction.  This research focuses on the preparation of PET ligands for the 
mGluR5 subtype receptor.   
  
3-fluoro-5-(pyridin-2-ylethynyl)benzonitrile (PEB) and 3-fluoro-5-((6-
methylpyridin-2-yl)ethynyl)benzonitrile (MPEB) are the two of the drugs of interest for 
this research.  Previously reported 
18
F-radiolabeling techniques for the preparation of 
compounds of this class involved a halogenated precursor with KF in DMSO and using 
microwave heating.  This strategy yielded approximately 4% RCY (“RCY” in this thesis 
refers to decay-corrected yield).  We chose this class of compounds as a target because it 
provides an opportunity to develop synthetic [
18
F]-fluoride methodology to make this 
drug widely available for neuroscience and neuromedicine.   
This method developed here for fluorination of aromatic rings can be expanded to 
achieve incorporation of  
18
F into aromatic amino acids.  Amino acids have been known 
to target tumor cells specifically.  In conclusion, this newly developed fluorination 
methodology opens a door to a variety of compounds that can be used for PET imaging 
studies.         
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CHAPTER ONE 
Positron emission tomography (PET) is a non-invasive imaging technique used to 
visualize physiological and biological processes in real time.
1
  Compounds are tagged 
with a radioactive isotope, allowed to diffuse to the appropriate biological target and 
pinpointed by determining the source of the emitted radiation.  Figure 1 shows commonly 
used PET radiotracers and their uses. 
 
 
Figure 1. Commonly used radiotracers for PET imaging.
1
 
In PET, the radionuclide label decays by emitting a positron, a positively charged 
particle of negative mass.  The positron is emitted with significant kinetic energy, but it 
slows down within ~ 1 mm as it collides with an electron, after which it annihilates an 
electron.  This matter-antimatter reaction produces two gamma rays (-rays) emitted at 
180
o
, as shown in Figure 2.  The gamma-rays are detected by a scintillation detector, and 
the simultaneity of the detection events is used to determine the path of the emitted 
gamma ray.  Localization of the drug is determined by counting the number of rays 
passing through various regions of the space within the detector.  Because PET provides 
no structural information, images are often coupled with a CT scan to give physiological 
landmarks.   
11 
 
 
A.      B. 
         
 
 Figure 2. PET imaging. A. Schematic diagram showing the process and apparatus 
for collecting a pet scan. Modified from Nature Reviews, 4, June 2004, 457-469.  B. 
Cartoon showing the nuclear processes leading to the production of gamma rays.  
Several radioactive isotopes used for PET imaging are listed in Table 1.  The most 
commonly used radionuclides are 
11
C, 
13
N, 
15
O and 
18
F.
2
  These radionuclides are 
desirable for radiopharmaceuticals because they are easy to incorporate into ligands 
without perturbing significantly the ligand’s affinities for their biological receptors.  11C 
appears to be an excellent candidate for PET imaging.  However, the extremely short 
half-life (20.4 minutes), severely constrains the types of synthetic reactions that can be 
used to introduce it.  While using a radionuclide with a short half-life seems 
counterintuitive; 
13
N (10 min) and 
15
O (2 min), have been applied to PET-based 
monitoring of myocardial blow flood and cerebral blood flow, respectiviey.
3
  Some 
advantages of using a short half-life radionuclide are that the overall dose exposure of 
12 
 
both patient and clinicians are low, and allows for repeat imaging experiments to be 
performed in a single day without requiring a patient to stay overnight at a hospital.   
18
F-Fluorine is in some sense an ideal radioactive isotope for PET imaging.  
18
Fluorine has a half-life (110 min) that allows for moderately complex synthetic 
transformations to be performed.  The half-life is sufficiently long to permit even a 
multistep synthesis, while still providing a highly radioactive compound.  The half-life is 
sufficient to allow transportation of the drug to a clinical setting away from the original 
cyclotron laboratory.  Another reason that 
18
F is such an attractive candidate for PET 
imaging is due to the emitting of low energy positron upon decay (0.64 MeV), the 
positron (+) travels a short distance before it is annihilated (~ 1 mm).   
Isotope Half-life 
 
Maximum 
Energy 
(MeV) 
Mode of 
Decay 
(%) 
Theoretical  
Specific 
activity 
(GBq/umol) 
18
F 110 min 0.64  + (97%) 
EC (3%) 
6.3 x 10
4
 
11
C 20.3 min 0.97 + (99%) 3.4 x 10
5
 
13
N 10 min 1.20 + (100%) 7.0 x 10
5
 
15
O 2 min 1.74 + (100%) 3.4 x 10
6
 
76
Br 16 hrs 4.0 + (57%) 
EC (43%) 
7.2 x 10
3
 
124
I 41.8 
days 
2.14 + (25%) 
EC (75%) 
1.15 x 10
3
 
68
Ga 68.1 min 1.90 + (89%) 
EC (11%) 
1.02 x 10
5
 
64
Cu 12.7 hrs 0.655 + (19%) 
EC (41%) 
+ (40%) 
9.13 x 10
3
 
  Table 1. Properties of Commonly Used Positron-Emitting Radionuclides
3
 
Structurally, fluorine is advantageous to incorporate into molecules of interest.  In 
chemical transformations, fluorine can be used to replace a hydrogen; although it may be 
13 
 
more advantageous to replace an oxygen or a hydroxyl group.  Fluorine and oxygen are 
sterically similar with Van der Waals radii of 1.52 and 1.47, respectively.
1
  Fluorine and 
oxygen are more electronically similar than fluorine and hydrogen; with electronegativity 
scores of 2.20 (H), 3.44 (O) and 3.98 (F).
1
  Although in some cases changing the polarity 
of a bond (C-H to C-F) can increase the potency of the drug.
4 
Currently, the dollar value of the PET market is projected to reach $5.4 billion in 
Europe and the United States by 2015.
5
 
1.2  Metabotropic Glutamate Receptors  
L-Glutamate is a major excitatory neurotransmitter in the central nervous system 
(CNS). Glutamate is regulated by two types of glutamate receptors; ionotropic and 
metabotropic. These two protein receptors can be further categorized into two types 
based upon their mechanisms of action.
6 
 Ionotropic glutamate receptors are ligand-gated 
ion channels.
6
  The ion channels allow the transport of K
+
, Na
+
 and Ca
2+
.  The flow of 
cations causes the neuron to become polarized and send signals down the neuron.  
Metabotropic glutamate receptors (mGluR) are G-coupled protein receptors; this receptor 
type is responsible for modulation of synaptic transmission.
7
  This family includes 
GABAb, pheromone, and Ca
2+
 sensing receptors.   
  There are eight members (mGluR1-8) of the mGluR family.  These eight 
proteins are distinguished on the basis of their sequence homology, second messenger 
coupling, and pharmacology.  Group I (mGluR1 and mGluR5) couple via an alpha G-
protein (Gq/G11) to phospholipase C.
8,11
 Phospholipase C is an enzyme that is involved 
in hydrolysis of phospholipids into diacylgylcerol and the corresponding phosphorylated 
14 
 
head group. The mechanism of this biochemical response begins with binding of 
glutamate to the receptor which catalyzes GTP-GDP exchange on the associated G 
protein; this energy transfer activates the G protein.  The activated G protein then 
activates a specific membrane bound phospholipase C (PLC).  PLC catalyzes production 
of two secondary messenger molecules: diacylglycerol and inositol 1,4,5-trisphosphate 
(IP3).
7
  IP3 binds to receptors on the endoplasmic reticulum and causes Ca
2+
 to be 
released.
7
  Group II (mGluR2 and mGluR3) and group III (mGluR4, 6, 7, 8) couple to a 
heterotrimeric G-protein (Gi/Go) to inhibit adenylyl cyclase activity.
6
 Andenylyl cyclase 
catalyzes the production of cAMP from ATP.  Most mGluR5s are located in the 
mammalian CNS and glial cells.  Group I is mainly located in a postsynaptic portion of 
the neuron, while groups II and III are found in the presynaptic part of the neuron and 
their main function is control of neurotransmitter release.  
A large, extracellular bi-lobed N terminal domain, characteristic of all mGlu 
receptors, is tethered with a cysteine-rich region.
9
  The cleft between the bi-lobed regions 
is the glutamate binding site.  The N-terminal domain is tethered to the seven 
transmembrane helical domain, that is anchored to the membrane.  Glutamate binds to the 
extracellular bi-lobed domain.   The seven transmembrane helical domain contains 
binding sites for noncompetitive positive and negative allosteric ligands.  A 
noncompetitive ligand is defined as one that does not bind at the same site as the 
endogenous glutamate, and therefore does and there for does not compete directly with 
glutamate.       
15 
 
 
Figure3.
9
  Cartoon of an mGlu receptor. 
On the basis of the widespread distribution of mGluR5 throughout CNS, 
particularly in regions that play essential roles in motor coordination and movement, it is 
thought that dysfunction of these receptors is implicated in neurological diseases, 
including anxiety, epilepsy and Alzheimer’s.10  For example, Parkinson’s is linked to an 
overexpression of mGluR5, so it is believed that inhibiting this receptor may  offer an 
opportunity for treatment of this disease.
10
  Currently, several pharmaceuticals 
companies(Pfizer, Eli Lilly & Co, and Novartis) are exploring Parkinson’s therapeutic 
drug discovery efforts featuring mGluR5 as the target receptor.
9
 
1. 3 mGluR5 Antagonists 
Glutamate, the endogenous ligand for mGluR5, is actually a poor starting point 
for developing a specific PET imaging agent because glutamate binds to ionotropic and 
metabotropic receptors, and would not have receptor specificity.  Research was focused 
on noncompetitive antagonists of mGluR5.  These types of compounds are advantageous 
16 
 
due to the fact they will not compete with endrogenous glutamate and not decrease the 
ligand-receptor sensitivity.
10
  Figure 4 shows noncompetitive mGluR5 antagonists. 
 
Figure 4. Noncompetitive mGluR5 antagonists 
High throughput screening of a compound library yielded the first noncompetitive 
mGluR5 antagonists  in 1999.  This work was performed by Mark Varney at SIBIA 
Neurosciences, gave the compounds SIB1757 and SIB1892, shown in Figure 4.
12
        
These compounds are selective, noncompetitive antagonists, and do not bind to the 
glutamate receptor site in the N-terminal region of the receptor. This binding property 
helps make these compounds more selective for the mGluR5.  SIB1757 and SIB1892 
were used as a starting point for medicinal chemistry.  It was determined that replacement 
of the double bond between the aromatic rings with a triple bond yielded higher 
antagonist activity.
10
 These new structures, MPEP and MTEP do not resemble glutamate 
at all, feature appropriate lipophility, and have good blood-brain barrier permeablilty.
10
 
With an appropriate set of mGluR5 antagonists identified, PET could be used to 
image glutamate receptor distribution in the brain.  Efforts were put toward heteroaryl 
acetylenes labeled with 
18
F or 
11
C.  Figure 5 shows the insertion of radioactive nuclides  
17 
 
into targets reported to have the best binding profile for PET imaging studies.
10
 Two 
compounds that are of interest to the DiMagno lab are 3-fluoro-5-(pyridin-2-
ylethynyl)benzonitrile (PEB) and 3-fluoro-5-((2-methylthiazol-4-yl)ethynyl)benzonitrile 
(MTEB).   [
18
F]-PEB is sufficiently lipophilic to cross the blood brain barrier, with a 
LogD (lipophilicity coefficient) value of 2.8.  A LogD value between 2 and 3 is 
considered optimal for penetration of a compound in the brain.
10   
[
18
F]-PEB is extremely 
potent; the ki value for the mGluR5 protein is 0.2 nM.  A metabolism study was 
performed on [
18
F]-PEB and showed that 78% of the injected radioactivity (decay 
corrected) was found in the brain 30 minutes after administration of the radiotracer.     
  
 
Figure 5.PET radioligands for the mGluR5 subtype receptor. 
The biochemistry of PEB has been investigated extensively.
14,15
  The precursors 
to the radioactive drug ([
18
F]-PEB) have been synthesized in high yields, but currently 
employed fluorination techniques have produced [
18
F]-labeled PEB and MTEB in only 4 
± 0.9% and 4 ± 0.6%, respectively.
13
  In PEB and MTEB we have clearly identified, 
potentially valuable radioligands for PET neuroimaging, but there are no effective 
synthetic methodologies for preparing them.  This thesis describes my approach to 
preparing these compounds using novel diaryliodonium salt precursors.         
18 
 
CHAPTER TWO 
2.1 Possible Fluorination Techniques    
 Approximately one third of all currently prescribed pharmaceuticals contain at 
least one fluorine atom.  Most often fluorine substituents are incorporated to control drug 
catabolism from cytochrome p450 activity.  Fluorination of oxidatively sensitive 
aromatic rings is a particularly common tool of the trade to enhance lifetime.  Typical 
fluorination methods require harsh conditions which are not compatible with many 
functional groups; to utilize these methods scientist install the fluorine substituents early 
in the synthesis.  Some traditional methods to fluorinate aromatic rings include Balz-
Schiemann (B.S) and nucleophilic substitution (SnAr) of electron-deficient arylhalides 
with KF.
15
  The Balz-Schiemann reaction converts aryl amines to aryl fluorides, via a 
diazonium salt intermediate.  Preparatory of the aryl diazonium salt typically requires 
acidic conditions, which may be problematic with particular functional groups.   For 
synthesis of PET radiotracers,  incorporation of [
18
F] fluoride must be performed toward 
the end of the synthesis because the short half-life of the isotope (110 min) precludes 
time consuming, multistep procedures subsequent to fluorination.  Some new 
methodologies have been developed recently that describe late stage introduction of 
fluoride into electron-rich aromatic rings.   
 One possible method to increase the fluorination yield is to utilize transition metal 
catalysts, specifically palladium.  Figure 5 shows a proposed palladium-catalyzed 
fluorination mechanism recently published by Buchwald and co-workers.
16  This method 
has a tolerance of many functional groups which broadens the substrate scope to highly 
19 
 
complex targets. While the idea of a catalytic system seems attractive as a means to 
fluorinate aromatic rings it is currently only practical for 
19
F incorporation.  This process 
requires high catalyst loading, and a long reaction time (12 h), which is not compatible 
with 
18
F incorporation.  
 
Figure 6.
16
 Metal catalyzed fluorination. 
 Electrophilic fluorination procedures have been used for the preparation of PET 
radioligands.
4
  Electrophilic methods rely on the generation of 
18
F-labeled F2.  [
18
F2] is 
produced via bombardment of gas containing neon and 0.1% 
19
F2 with deuterons.  
Scheme 1 shows the nuclear reaction used to produce electrophilic 
18
F, and application of 
18
F2 in a fluorodemetalation reaction to produce  [
18
F]FDOPA.
17
    
20 
 
 
 Scheme 1. A. Process by which electrophilic 
18
F2 is produced.  B. Incorporation of 
18
F2 
into DOPA, used for PET imaging of brain dopamine metabolism. 
 There is an inherent problem associated with electrophilic fluorination: the 
specific activity of the [
18
F]-fluorinated radioligands is always low.  This problem arises 
because of two reasons; one, the [
18
F]-labeled F2 only has one 
18
F atom, thus the 
maximum achievable radiochemical yield is only 50%
3
, and two, the concentration of gas 
is 1,000-10,000 times that of the 
18
F atom concentration.  This dilution results in PET 
ligands that are contaminated with huge amounts of the 
19
F-labeled compound.  The 
presence of the nonradioactive PET ligand can degrade image quality and lead to 
secondary drug effects and toxicity.       
 There has been a drive to develop no-carrier added fluorination reactions to avoid 
the pitfalls of carrier-added fluorination.  This has been achieved through the use of 
nucleophilic radiofluroinations.
3
  The amount of radioactivity that can be produced in a 
commercial cyclotron by proton bombardment of an 
18
OH2 target is approximately 1000 
GBq (~30 Cures).  Specific activity is the amount of radioactivity per mole of compound.  
21 
 
For per 18F-, the specific activity is on the order of 1 Curie (376 Bq) per 10 ng (~60 
GBq/nanomole).     
Direct introduction of no carrier-added fluoride is the reaction of choice for 
preparing high specific activity material.  Direct nucleophilic fluorination reactions are 
severly limited in scope, generally the arene to be fluorinated must possess an electron-
withdrawing group.  The reaction must be carried out under extremely dry conditions.  
The fluoride ion, 
18
F
-
, is a poor nucleophile in an aqueous environment.  Fluoride can be 
activated with the addition of a cryptand and tetra-n-butylammonium salt, in most cases 
these are Kryptofix 2.2.2.(cryptand) and potassium carbonate (tetra-n-butylammonium 
salt).  Nucleophilic radio-fluorinations of aliphatic systems usually follow a Sn2 
mechanism in dipolar aprotic solvents.  Classically, only activated (NO2, CN, CHO, and 
COOR) aromatic rings were needed to incorporate the 
18
F moiety, but not all clinically 
relevant biomolecules contain an activating group, there is a drive to become creative 
with the chemistry.         
2.2 Using 
18
F as a labeling agent 
The current technique for production of 
18
F is proton bombardment of H2O
18
.  
Following bombardment, the [18F]-fluoride is trapped on an ion exchange resin, and 
eluted with aqueous carbonate or bicarbonate (Figure 6).  Residual water is removed by 
multiple azeotropic distillations with acetonitrile.     
22 
 
 
Figure 7.  Method for isolation of 
18
F ion from cyclotron product. 
The addition of Kriptofix 2.2.2 helps to solubilize the fluoride ion in polar aprotic 
solvents, and sequesters the cation to bolster the fluoride ion nucleophilicity.   
2.3 Diaryliodonium salts 
 Diaryliodonium salts, λ3diaryl-iodanes, were first synthesized in 1894.18  These 
compounds are air and moisture stable, which make them attractive reagents in organic 
synthesis.  Scheme 3 shows two reactions that diaryliodonium salts are commonly used 
in.  Diaryliodonium salts can be formed as either symmetrical or unsymmetrical salts 
(Scheme 3.a); this avoids any selectivity issues when reductive elimination occurs.  The 
nucleophilic displacement of the iodonium salt will reductively eliminate to the desired 
ring.  It is believed that the iodonium salts proceed through a reductive elimination 
mechanism, in which the aryl-group is transferred to the nucleophile (Scheme 3.b).  
23 
 
Iodonium salts can act as aryl-iodides and transfer the aryl group and ligand to a metal; as 
in an oxidative addition.
18
 
 
Scheme 2.
18
 Some common uses for diaryliodonium salts.  (a) General structure 
for diaryliodonium salts, X = Cl, Br, I OTf, OTs. (b) Reaction of diaryliodonium 
salts and nucleophiles. (c)Metal catalyzed reactions of diaryliodonium salts, 
yielding cross coupling products.   
Reductive elimination of diaryliodonium salts would seem to be a facile way to 
introduce 
18
F in an efficient and selective manner.  In Scheme 4 it can be seen that this 
method is reported to work on several systems with diverse functionality.   
It has been shown that thermal decomposition of diaryliodides favor 
functionalization on the electron-poor ring, while the iodine stays on the electron-rich 
ring.
18
  The directing group in iodonium reactions can vary.  Scheme 4 shows the 
directing group as a p-methoxy phenyl, but the directing group can be any aryl group, 
most notably 2-thienyl and p-cyclophane. 
 
24 
 
 
Scheme 3. Some examples of radiofluroination with Diaryliodonium salts.
1
  RCY 
is decay-corrected radiochemical yield. 
2.4 Established protocol for mGluR5 synthesis 
  
Scheme 4. Synthetic approach for radio-labeled PEB.
13
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Hamill and coworkers (Merck Research Laboratories) were the first to synthesize 
the mGluR5 ligand.  Most chemical transformations used in PET radiotracer synthesis 
take less than 20 minutes.  While the reaction time is suitable for PET radiotracer 
synthesis, the yield was atrocious.  This method left much ground to make up if this was 
to be widely utilized as a synthetically useful reaction. 
2.5 New Synthetic Approach for F-PEB 
There is a need for a new method for nucleophilic fluorination, one that increases 
yield and maintains the short reaction time.  The DiMagno group has developed a method 
for fluorination of electron deficient aromatic rings.  This method utilizes hypervalent 
iodine to introduce fluorine in relatively high yields (>70%).  This newly developed 
iodonium chemistry begins with a halogenated precursor.   
    
 
  Scheme 5. The preparation of 3-bromo-5-((6-methylpyridin-2-
yl)ethynyl)benzonitrile 
 Reagents and conditions: (a) (trimethylsilyl) acetylene, PdCl2(PPH3)2, CuI, Et3N, 
90 
o
C; (b) KOH, MeOH, room temp; (c) 3,5-dibromobenzonitrile, PdCl2(PPh3)2, 
CuI, Et3N, 90 
o
C. 
26 
 
The brominated precursor of PEB (1, Scheme 5) was synthesized in 2005 by the 
Tamagnan group.
15
  The commercially available starting material, 2-bromopyridine, was 
subjected to Sonogashira coupling with TMS-acetylene, using Pd (II).  This first synthetic 
step took about 12 hours at 90 
o
C and had a very high yield, 96%.  The 2-
(trimethylsilylethnynyl)pyridine (2) product was easily purified by silica gel flash 
chromatrography and deprotected with KOH and MeOH, in essentially quantitative yield 
(3).  A second, more challenging Sonogashira coupling reaction was performed with the 
deprotected alkyne and 3,5-dibromobenzonitrile.  The reaction produced the desired 
brominated pyridinylethnylyl benzonitrile (4), but also a large amount of Glaser coupled 
diyne, which was only removed with difficulty from the desired product.  To overcome 
this problem, the alkyne concentration was kept low  in the presence of a gross excess  of 
the dibromobenzonitrile.  The alkyne was added in small aliquots over the course of 
several hours.   Palladium catalyzed stannylation (5) was performed on the brominated 
benzonitrile precursor.  An important aspect of the stannylation step that should be noted 
was that the reaction worked best when excess (4 equiv.) of Bu3Sn2 was used to eliminate 
cross coupling products 
 
Scheme 7. Stannylation of 3-bromo-5-(pyridin-2-ylethynyl)benzonitrile.  
 . 
27 
 
 
Scheme 8. Iodonium chemistry of PEB.  Reagents and conditions: (a)TMS-TFA 
acetonitrile;  (b) CH3CN, 40 
o
C, 14 hrs. (c) H2O, NaPF6; (d) Ion-exchange 
column.  
   Preparation of the PEB derived diaryliodonium triflate is shown in Scheme 7.  
The stannane condensed smoothly with 4-methoxyphenyliodonium diacetate upon 
activation with trifluoroacetic acid (TFA).  In this process, TFA replacing once acetate 
group with a trifluoroacetate, making the I(III) center more electrophilic.  Isolation of the 
diaryliodonium salt was facilitated by the addition of aqueous NaPF6 to precipitate it 
from water, and extraction with hexane to remove the various tributyl-impurities. Ion-
exchange (Amberlite-IRA 400 ion exchange resin) to the triflate was facile. 
 
 
Scheme 9. Fluorination procedure for PEB.  A. TMAF, CH3CN.  B. Pumped off CH3CN, 
dissolve in C6H6, filter and heat to 140 
o
C. 
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 Our laboratory has optimized procedures for thermal decomposition of 
diaryliodonium salts.
19
  It was found that the use of a low polarity, non-coordinating 
solvents,  would improve yields of fluorinated arenes and suppresses noxious side 
products  arising from electron-transfer and disproportionation processes.  Prior to this 
work, the use of benzene as a solvent in PET radiotracer synthesis was unprecedented;  
the typical solvents are polar aprotic (CH3CN, DMF).  Also, our laboratory has shown 
that the removal of electrolytes also improves yields significantly.  Inorganic salts 
produced from ion exchange should not act in the thermal decomposition of 
diaryliodonium salts, but they may act in ligand exchange and increase the I-F 
dissociation rate and dissociation constant.
19
 
 To prepare the [
19
F]-fluorinated PEB derivatives the triflate salt was dissolved in 
an acetonitrile solution of tertamethyl ammonium fluoride (TMAF).  Exchange of triflate 
and fluoride is instantaneous and verified by 
19
F NMR spectroscopy.  To remove the inert 
electrolyte (TMA-OTf), the acetonitrile was evaporated and the remainder was dissolved, 
to the extent possible, in dry d6-benzene.  This solution was passed through a 0.20 um 
PTFE syringe filter.  Reductive elimination of F-PEB was achieved simply by heating the 
benzene solution at 140 
o
C (sealed tube) for 20 minutes.  Fluorination was very selective, 
no fluoroanisole was formed.  The F-PEB was separated from 4-iodoanisole by using a 
column chromatography (silica gel, ethyl acetate : hexane, 85:15) (70%). 
 There has been research attention placed on mGluR5 radiotracers that contain a 
methyl group adjacent to a nitrogen atom in one of the rings.15  PEB was taken as a 
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template, and methyl-Pyridinylethynyl Benzonitrile was investigated as a potential target 
for this project.  As expected the synthetic strategy was high yielding, 60% fluorinated 
drug; and highly selective, no fluoroanisole formation.   
Scheme 10. Synthetic strategy for M-PEB. 
The fore mentioned synthesis was performed on methyl-Pyridinylethynyl 
Benzonitrile, MPEB.  All reagents and conditions were exactly the same; detailed 
characterization can be found in the experimental section. 
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   CHAPTER THREE 
3.1 Expansion of Methodology to Aromatic Amino Acids  
 Glucose (2FDG) has been used in PET imaging to show tumor location.  Tumors 
show an increase of glucose uptake and metabolism, this may is due to the higher energy 
demands of a rapidly proliferating cell and over expression of glucose transporters.  A 
drawback to using glucose as a PET tracer is that it is not specific, and it would also show 
up in areas of normal high glucose usage, i.e. the brain and the heart.   Many amino 
acids have been investigated as radiotracers to solve the high background response in 
2FDG.  R. M. Johnstone in 1965 showed that amino acid transport and protein synthesis 
is increased in tumor cells.
20
  Amino acids can be used as radiotracers, and can be used to 
visualize amino acid accumulation in tumor tissue; in some cases the amino acid tracers 
are actually incorporated into growing protein inside  tumor cells.  Advantages of using 
amino acids as radiotracers is that they have a higher specificity for particular cancer 
cells, especially in the brain, and are less likely to give rise to high background signals, as 
is the case for 2-FDG.
21
  Figure 7 shows two very recent fluorinated amino acid 
radiotracers used in PET imaging.   
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Figure 8. Current amino acid analogues used for PET imaging.  FET, 
[18F]fluoroethyl tyrosine; BAY 85-8050, 4-[
18
F]Fluoroglutamic Acid. 
[
18
F]fluoroethyl tyrosine, [
18
F]FET, is currently under investigation for targeting tumor 
cells in the brain.
22
  [
18
]FET has one major drawback due to the radiotracer being trapped 
in peripheral tissue, giving rise to a large background signal.  To overcome this challenge 
BAY 85-8050 was developed. 
23
  This 
18
F glutamate derivative has been shown to be  
taken up selectively in lung and colon cancer cell lines.
23
  These initial results 
demonstrates the potential for 
18
F labeled amino acid radiotracers to be used in oncology 
imaging. 
Although few examples of 
18
F-labled amino acids as PET imagers are known,    
Figure 8 shows the variety of aromatic amino acids that can be 
18
F radio labeled with the 
techniques developed in the DiMagno laboratory.  [18F]-labeled aromatic amino acids 
present significant challenges for their synthesis with n.c.a. fluoride; protection schemes 
need to be developed that are compatible with I(III) salt formation and nucleophilic 
fluorination.    
 
Figure 9. Possible aromatic amino acid radio tracers.  Red X implies position of 
18
F isotope.  A. phenylalanine, b. tyrosine, c. tryptophan, d. histidine. 
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In our approach the position ultimately bearing the 
18
F-label must be able to be 
halogenated selectively, and from the halogenated precursor the iodonium chemistry 
would be identical to the procedure described in Chapter 2.  
There is a need to have a high yielding fluorination technique in [
18
F]-PET.  The 
new method  described here, which utilizes iodonium salts, is not only high yielding, but 
also fits in with the short half-life and fast synthesis that is required for 
18
F chemistry.  
This opens the door for usage of 
18
F labeled drugs in PET imaging.   
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EXPERIMENTAL PROCEDURES 
 
2-((trimethylsilyl)ethynyl)pyridine 
Ref: Bioorg. Med. Chem. Let. 16 (2006) 4788-4791 
Into a 50 mL schlenk tube was placed triethylamine (15 mL), 2-bromopyridine (2.0g, 
12.66 mmol), and trimethylsilylacetylene (1.65 mL, 15.12 mmol).  The reaction mixture 
was freeze, pumped, thawed three times.  The reaction mixture was transferred to a small 
storage tube charged with Pd(PPh3)2Cl2 (0.145g, 5 mol %), CuI (0.0049 g, 5 mol %), and 
a flea stir bar.  The solution was capped and heated to 90 
o
C for 12 hrs.  Once the reaction 
was completed the storage tube was cooled to room temperature and contents run through 
a silica plug with ethyl acetate, to remove the catalyst.  The elutant was concentrated via 
rotary evaporation.  The concentrate was purified by flash chromatography (silica gel, 95 
: 5 hexanes : ethyl acetate elutant).  The solvent was removed in vacuo leaving the 
product as a brown oil. (2.1 g, 95%)  
1
H NMR (400 MHz, CDCl3):  = 8.5 (dd, 1 H, J1 = 0.4 Hz, J2 = 4.8 Hz), 7.71 (dt, 1 H, J1 
= 1.6 Hz, J2 =  7.8 Hz), 7.4 (td, 1 H, J1 = 0.8 Hz, J2 = 7.8 Hz), 7.3 (ddd, 1 H, J1 = 4.8, J2 = 
3.6, J3 = 7.8), 0.25 (s, 3 H). 
13
C NMR (100 MHz, CD3CN):  = 151.1, 143.63, 137.46, 
128.29, 124.47, 118.29, 105.12, 94.72, -0.25.   
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2-((trimethylsilyl)ethynyl)pyridine 
In a 100 mL round bottom flask was placed methanol (20 mL), KOH (0.18g, 3.2 mmol), 
and 2 trimethylsilylethynyl pyridine (300 mg, 1.7 mmol).  Solution was allowed to stir at 
room temperature for 2 hrs.  The solvent was removed in vacuo.  Concentrate was 
combined with 10 mL of water.  Product was extracted with three washes of ethyl 
acetate.  Product was dried over sodium sulfate and solvent was removed via rotary 
evaporation yielding a light yellow oil.  No further purification was necessary. ( 0.176g, 
100 %) 
1
H NMR (400 MHz, CDCl3): = 8.55(d, 1 H, J = 4.8 Hz), 7.62 (dt, 1 H, J1 = 6.4 Hz, J2 = 
1.6 Hz), 7.44 (d, 1 H, J = 8Hz), 7.22 (t, 1 H, J = 5.6 Hz), 3.13 (s, 1 H). 
13
C NMR (100 
MHz, CDCl3) :  = 150.02, 142.32, 136.16, 127.45, 123.41, 82.73, 77.14.  
 
 
3-bromo-5-(pyridin-2-ylethynyl)benzonitrile 
 Into a schlenk tube was placed dibromobenzonitrile (4.0 g, 15.7 mmol), 2-ethynyl 
pyridine (1.84 g, 15.7 mmol), and triethylamine (~50 mL).  Reaction mixture was 
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degassed by freeze, pump, thawing three times.  Solution was transferred to a storage 
tube containing Pd(PPh3)2Cl2 (0.375 g, 3 mol %), and a catalytic amount of CuI.  Storage 
tube was capped and heated to 90 
o
C for 18 hrs.  Once the reaction was completed the 
storage tube was cooled to room temperature and contents run through a silica plug with 
ethyl acetate, to remove the catalyst.  The solvent was concentrated via rotary 
evaporation.  The concentrate was purified by flash chromatography (silica gel, 80 : 20 
hexanes : ethyl acetate).  The solvent was removed in vacuo leaving the product was an 
off white solid (1.99, 45 %).   
1
H NMR (400 MHz, CDCl3):  = 8.6 (dd, 1 H, J1 = 1.4 Hz, J2 = 2.8 Hz), 7.9 (t, 1 H, J = 
1.6 Hz), 7.8 (dt, 1 H, J1 = 1.6 Hz, J2 = 7.6), 7.7 (td, 1 H, J1 = 1.6 Hz, J2 = 7.6 Hz), 7.5 (d, 
1 H, J = 8 Hz), 7.3 (ddd, 1 H, J1 = 1.2 Hz, J2 = 3.6 Hz, J3 = 7.6 Hz).  
13
C NMR (100 MHz, 
CDCl3):  = 150.36, 142.08, 138.83, 136.41, 134.62, 133.71, 127.54, 125.61, 123.74, 
122.85, 116.54, 114.42. 91.95, 84.80.  
 
 
3-(Pyridin-2-ylethynyl)-5-(tributylstannyl)benzonitrile 
3-Bromo-5-(pyridin-2-ylethynyl) benzonitrile (0.500g, 1.77 mmol) was dissolved in a 
minimal amount of benzene and transferred to a heavy-walled glass storage tube 
equipped with a threaded PTFE closure. Hexabutylditin (3.07g, 5.30 mmol), and benzene 
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(10 mL) were added.  Bis(tri-tert-butylphosphine)palladium was prepared as follows: 
Pd(dba)2 (80.8 mg, 0.0883 mmol) and P(t-Bu)3 (44.6 mg, 0.221 mmol) were dissolved 
separately in benzene and combined.  The catalyst mixture was allowed to stir until the 
solution changed from deep purple to dark red, and the solution was passed through a 0.2 
m membrane filter and added directly to the storage tube.  The reaction flask was 
sealed, protected from light by shielding with aluminum foil, and the solution was heated 
at 110 °C for 3 days.  The solution was cooled, the benzene was removed in vacuo, and 
the crude product was purified by flash chromatography (silica gel, 93:7 
hexanes:triethylamine eluant).  The solvent was removed in vacuo leaving the product as 
a viscous yellow oil (0.350g, 40%). 
1
H  NMR (300 MHz, CD3CN):  = 8.4 (d, 1 H, J = 4.2 Hz), 7.87 (s, 1 H), 7.56 (s, 1 H), 
7.29 (d, 1 H, J = 1.8 Hz), 7.20 (s,  1 H), 6.88 (dt, 1 H, J1 = 2.0 Hz, J2 = 1.9 Hz), 6.50 (dd, 
1 H, J1 =  5.0 Hz, J2 = 7.8 Hz), 1.542 (t, 1 H, J = 8.0 Hz), 1.31 (q, 6 H, J = 16 Hz), 1.15 
(h, 6 H, J = 8.2 Hz), 0.884 (t, 9 H, J = 7.2 Hz). 
13
C NMR (75 MHz, CD3CN):  = 150.4, 
142.8, 139.0, 135.4, 129.9, 127.7, 127.0, 123.4, 122.7, 118.3, 113.2, 29.0, 27.3, 13.6, 9.6. 
HR-FAB MS: (M+H)
+
 = 495.1831 m/z (calcd for C26H34N2Sn,  494.174)  
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(3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
hexafluorophosphate 
3-(Pyridin-2-ylethynyl)-5-(tributylstannyl)benzonitrile (25.0 mg, 0.0500 mmol), 4-
methoxyphenyliodonium diacetate (35.8mg, 0.0999 mmol), and trimethylsilyl 
trifluoroacetate (20.5mg, 0.110 mmol) were combined in CD3CN and placed in a J. 
Young NMR tube.  The reaction mixture was heated at 40 °C for 11 h, and its progress 
was monitored by 
1
H NMR spectroscopy.  Upon completion of the reaction, water (4.5 
mL) was added to precipitate tributyltin acetate and the solution was filtered.  Sodium 
hexafluorophosphate (25.19 mg, 0.150 mmol) was added to the filtrate and the 
precipitated (3-cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
hexafluorophosphate was collected by membrane filtration. The solid was redissolved in 
CH2Cl2 to remove it from the filter and the solvent was evaporated. The colorless solid 
was recrystallized from CH2Cl2/heptanes to give a colorless, crystalline solid. (14.6 mg,  
50%).    
1
H NMR (300 MHz, CD3CN)  = 8.63 (d, 1 H,  J = 4.8 Hz), 8.49 (d, 1 H, J = 1.2 Hz), 
8.40 (s, 1 H), 8.21 (d, 1 H , J = 0.8 Hz), 8.01 (d, 2 H, J = 9.2 Hz), 7.90 (t, 1 H, J = 7.6 
Hz), 7.68 (d, 1 H, J = 7.6 Hz), 7.48 (t, 1 H, J = 6.2 Hz), 7.10 (d,  2 H, J = 9.2 Hz), 3.86 (s, 
3 H); 
13
C NMR (75 MHz, CD3CN) d = 150.51, 141.36, 139.12, 138.22, 137.92, 136.81, 
127.89, 124.35, 118.44, 117.30, 115.64, 55.84; 
19
F NMR (282 MHz, CD3CN): -72.96 (d, 
6 F, J = 705 Hz); HR-FAB MS: (M-PF6)
+
 437.0149 m/z (calcd for C21H14IN2O, 
437.0145) 
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(3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
trifluoromethanesulfonate 
 (3-cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
hexafluorophosphate (52mg, 0.0894 mmol) was dissolved in a minimal amount (0.5mL) 
of acetonitrile.  The solution was passed through a 12 mm diameter column packed to a 
height of 10 cm with Amberlite-IRA 400 ion exchange resin (OTf) in acetonitrile.  
Evaporation of the eluted product yielded a colorless solid that was recrystallized from 
acetone/hexane to yield (3-cyano-5-(pyridine-2-ylethynyl)phenyl)(4-
methoxyphenyl)iodonium trifluoromethanesulfonate (52.0 mg, 100%)   
1
H NMR (300 MHz, CD3CN)  8.64 (d, 1 H, J = 7.0 Hz), 8.47 (s, 1 H), 8.39 (s, 1 H), 
8.20 (s, 1 H), 8.06 (d, 2 H, J = 9.3 Hz), 7.82 (d, 1 H, J = 7.5 Hz), 7.63 (d, 1 H, J = 8.4 
Hz), 7.40 (d, 1 H, J = 7.0 Hz), 7.09 (d, 2 H, J = 9.0 Hz), 3.86 (s, 3 H); 
13
C NMR (75 
MHz, CD3CN): 163.79, 159.71, 141.49, 139.30, 138.29, 138.22, 118.46, 116.54, 113.15, 
81.87, 55.85, 55.04; 
19
F NMR (282 MHz, CD3CN): -79.35 (s); HR-FAB MS: (M-OTf)
+
 
437.0156 m/z (calcd for C21H14IN2O, 437.0145) 
 
42 
 
3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile 
(3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
trifluoromethanesulfonate (25 mg, 0.0427 mmol) and TMAF (3.3mg, 0.0417 mmol) were 
combined in CH3CN to effect ion exchange. The solvent was removed in vacuo, the 
residue was treated with C6D6 (0.8 mL) and the solution was passed through a membrane 
filter (0.2 m pore size) directly into an NMR tube that was equipped with a PTFE valve.  
The reaction mixture was heated at 140 ºC for 15 minutes.  Product was purified by flash 
chromatography (silica gel, 85:15 hexanes:ethyl acetate eluant).  The solvent was 
removed in vacuo leaving the product as a crystalline white powder (7 mg, 70%)  
19
F NMR (376 MHz, CD3CN): -111.81 ( t) 
Preparation of an analytical standard of 3-Fluoro-5-(pyridine-2-
ylethynyl)benzonitrile 
A sample of 3-fluoro-5-(pyridine-2-ylethynyl)benzonitrile was performed by standard 
methods to provide an analytical HPLC standard.  2-Ethynylpyridine (100 mg, 0.971 
mmol) and 2-bromo-4-fluorobenzonitile (192 mg, 0.965 mmol) were dissolved separately 
in trimethylamine (5 mL) and placed into a heavy-walled glass storage tube equipped 
with a threaded PTFE closure.  The reaction mixture was degassed and transferred by 
cannula into a separate heavy-walled glass storage tube fitted with a threaded PTFE 
closure containing bis(triphenylphosphine)palladium dichloride (34 mg, 5 mol %) and 
CuI (4.3 mg, 5 mol %).  The reaction was capped and heated to 80 °C for 18 h.  The 
cooled solution was extracted from water using ethyl acetate, and the organic layer was 
dried over sodium sulfate.  Flash chromatography (silica gel, 95:5 hexanes:ethyl acetate 
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eluant) and evaporation of the solvent provided the  product as a light yellow solid.  
Recrystallization was performed with hexanes to yield colorless crystals. (64.7 mg, 30 %)  
1
H NMR  (400 MHz, CD3CN): 8.62 (dd, 1 H, J1 = 0.8 Hz, J2 = 3.4 Hz), 7.81 (dt, 2 H, 
J1=2.0 Hz, J2= 7.8 Hz), 7.66 (ddd, 1 H, J1 = 1.6 Hz, J2 = 2.6 Hz, J3 = 9.2 Hz), 7.62 (td, 1 
H,  J1 = 0.8 Hz, J2 = 8.0 Hz), 7.59 (ddd, 1 H, J1 = 1.2 Hz, J2 = 2.4 Hz, J3 = 8.4 Hz), 7.39 
(ddd, 1 H, J1 = 0.8 Hz, J2 = 5.0 Hz, J3 = 8.0 Hz); 
13
C NMR (75 MHz, CD3CN): 
168.87, 165.58, 155.70, 147.25, 141.99, 137.15, 137.10, 133.96, 130.96, 130.82, 
129.29, 128.83, 128.52, 125.43, 125.10, 119.65, 119.51, 96.57; 
19
F NMR (376 MHz, 
CD3CN): -111.81 ( t, 1 F); HR-FAB MS: (M+H)
+
 = 223.0674 (calcd for C14H7FN2, 
222.06) 
 
 
2-methyl-6-((trimethylsilyl)ethynyl)pyridine 
Into a 50 mL schlenk tube was placed triethylamine (30 mL), 2-bromo-6-methylpyridine 
(2.0g, 11.63 mmol), and trimethylsilylacetylene (1.36 mL, 13.95 mmol).  The reaction 
mixture was freeze, pumped, thawed three times.  The reaction mixture was transferred to 
a small storage tube charged with Pd(PPh3)2Cl2 (0.163 g, 2 mol %), CuI (0.044 g, 2 mol 
%), and a flea stir bar.  The solution was capped and heated to 90 oC for 12 hrs.  Once the 
reaction was completed the storage tube was cooled to room temperature and contents 
run through a silica plug with ethyl acetate, to remove the catalyst.  The elutant was 
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concentrated via rotary evaporation.  The concentrate was purified by flash 
chromatography (silica gel, 95 : 5 hexanes : ethyl acetate elutant).  The solvent was 
removed in vacuo leaving the product as a brown oil. (2.09 g, 95 %)  
1
H NMR (400 MHz, CDCl3): = 7.5 (t, 1 H, J1 = 7.6 Hz), 7.2 (d, 1 H, 7.6 Hz), 7.0 (d, 1 
H, 7.6 Hz), 2.5 (s, 3 H), 0.2 (s, 9 H).  
13
C NMR (100 MHz, CDCl3):  = 158.84, 142.31, 
136.25, 124.57, 122.85, 103.88, 94.16, 24.57, -0.24.  
 
2-methyl-6-((trimethylsilyl)ethynyl)pyridine 
In a 100 mL round bottom flask was placed methanol (33 mL), KOH (1.29g, 23.0 mmol), 
and 2 trimethylsilylethynyl pyridine (2.09 g, 17.9 mmol).  Solution was allowed to stir at 
room temperature for 2 hrs.  The solvent was removed in vacuo.  Concentrate was 
combined with 10 mL of water.  Product was extracted with three washes of ethyl 
acetate.  Product was dried over sodium sulfate and solvent was removed via rotary 
evaporation yielding a light yellow oil.  No further purification as necessary. ( 1.19g, 92 
%). 
1
H NMR (300 MHz, CDCl3):  = 7.56 (t, 1 H, J = 7.8 Hz), 7.32 (d, 1 H, J = 7.5), 7.15 (d, 
1 H, J = 7.8), 3.14 (s, 1 H), 2.57 (s, 3 H).  
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3-bromo-5-((6-methylpyridin-2-yl)ethynyl)benzonitrile 
 Into a schlenk tube was placed dibromobenzonitrile (3.15g,12.2 mmol), 2-ethynyl-6-
methyl pyridine (1.19g, 10.17 mmol), and triethylamine (~50 mL).  Reaction mixture was 
degassed by freeze, pump, thawing three times.  Solution was transferred to a storage 
tube containing Pd(PPh3)2Cl2 (3 mol %), and a catalytic amount of CuI.  Storage tube was 
capped and heated to 90 C for 18 hrs.  Once the reaction was completed the storage tube 
was cooled to room temperature and contents run through a silica plug with ethyl acetate, 
to remove the catalyst.  The solvent was concentrated via rotary evaporation.  The 
concentrate was purified by flash chromatography (silica gel, 85 : 15 hexanes : ethyl 
acetate).  The solvent was removed in vacuo leaving the product was an off white solid 
(1.78g, 59%). 
1
H NMR (400 MHz, CDCl3):  = 7.66 (s, 1 H), 7.6 (t, 1 H, J = 8 Hz), 7.5 (dq, 1 H, J1 = 
8.8 Hz, J2 = 1.6 Hz), 7.36 (d, 1 H, J = 8 Hz), 7.35 (dq, 1 H, J1 = 12 Hz, J2 = 1.2 Hz), 7.1 
(d, 1 H, J = 7.6 Hz), 2.6 (s, 3 H).  
13
C NMR (100 MHz, CDCl3):  = 163.08, 160.59, 
159.29, 141.28, 136.56, 131.39, 126.22, 124.83, 123.35, 119.38, 116.79, 114.39, 92.03, 
84.54, 24.66. 
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3-((6-methylpyridin-2-yl)ethynyl)-5-(tributylstannyl)benzonitrile 
3-bromo-5-((methylpyridin-2-yl) ethynyl) benzonitrile (1g, 1.97 mmol) was dissolved in 
a minimal amount of benzene and transferred to a heavy walled glass storage tube 
equipped with a threaded PTFE closure.  Hexabutylditin (3.44g, 5.90 mmol), and 
benzene (10ml) were added.  Bis(tri-tert-butylphosphine) palladium was prepared as 
follows: Pd(dba)2 (0.126 mg, 0.138 mmol) and P(t-Bu)3 (69.8 mg, 0.345 mmol) were 
dissolved separately in benzene and combined.  The catalyst mixture was allowed to stir 
until the solution changed from a deep purple to a dark red.  The catalyst mixture was 
passed through a 0.2 um membrane filter and directly to the storage tube.  The reaction 
flask was sealed, protected from light by shielding with aluminum foil, and the solution 
was heated to 110 
o
 C for 3 days.  The solution was cooled, the benzene was removed in 
vacuo, and the crude product was purified by flash chromatography (silica gel, 90:10 
hexanes:triethylamine eluant).  The solvent was removed in vacuo leaving the product as 
a viscous yellow oil (0.460 g, 46%).  
1
H NMR (400MHz, CD3CN):  = 7.93 (d, 1 H, J = 0.8 Hz), 7.84 (s, 1 H), 7.83 (s, 1 H), 
7.67 (t, 1 H, J = 7.8 Hz), 7.41 (d, 1 H, J = 7.6 Hz), 7.24 (d, 1 H, J = 8.0 Hz), 2.51 (s, 3 H), 
1.52 (q, 6 H, J = 8.6 Hz), 1.39 (s, 6 H, J =  6.9 Hz), 1.15 (t, 6 H, J = 7.8 Hz), 0.88 (t, 9 H, 
J = 7.35 Hz); 
13
C NMR (75 MHz, CD3CN):  = 159.30, 145.21, 143.31, 141.62, 139.69, 
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136.82, 134.44, 124.57, 123.22, 122.66, 118.18, 112.18, 90.53, 85.90, 28.66, 26.95, 
23.52, 12.92, 9.47;  HR-FAB MS: (M+H)
+
 = 509.1979 (calcd for C27H36N2Sn, 508.19)  
 
(3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-methoxyphenyl)iodonium 
hexafluorophosphate 
3-(pyridin-2-ylethynyl-6-methyl)-5-(tributylstannyl)benzonitrile (25.0 mg, 0.0420 mmol), 
diacetateiodoanisole (29.5mg, 0.0838 mmol), and trimethylsilyl-trifluroacetate (11.7 mg, 
0.0630 mmol)  were combined in CD3CN and placed in  J. Young NMR tube.  The 
reaction mixture was heated  to 40 °C for 12 hrs, the reaction was monitored by 1H NMR 
spectroscopy.  Upon completion of the reaction, the reaction mixture was combined with 
water (4.5g, 0.250 mol) to precipitate the tributyltin-acetate and the solution was filtered.  
The filtrate was combined with Sodiumhexaflurophosphate (25.19 mg, 0.150 mmol) and 
the precipitated (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-
methoxyphenyl)iodonium hexafluorophosphate was collected by membrane filtration.  
The solid was redissloved in CH2Cl2 to remove it from the filter and the solvent 
evaporated.  The colorless solid was recrystallized from CH2Cl2/heptanes to give a 
colorless, crystalline solid (12.5mg, 50%). 
1
H NMR (400MHz, CD3CN):  = 8.47 (s, 1 H ), 8.39 (s, 1 H), 8.20 (s, 1 H), 8.07 (d, 2 H, 
J = 8.1 Hz), 7.72 (t, 1 H, J = 8.0 Hz), 7.44 (d, 1 H, J = 8.0 Hz), 7.29 (d, 1 H, J = 8.0 Hz), 
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7.10 (d, 2 H, J = 9.2 Hz), 3.86 (s, 3 H), 2.52 (s, 3 H). 
13
C NMR (100 MHz, CD3CN):  = 
163.82, 159.59, 141.36, 140.57, 139.16, 138.29, 137.89, 137.10, 126.78, 125.09, 124.06, 
118.49, 115.66, 112.93, 101.28, 93.33, 82.99, 55.85, 23.46; 
19
F (376 MHz, CD3CN)  = -
72.79 (d, 6 F, 703.1 Hz); HR-FAB MS: (M-PF6)
+
 451.0299 m/z (calcd for C22H16IN2O, 
451.03)   
 
 
(3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-methoxyphenyl)iodonium 
trifluoromethanesulfonate 
(3-cyano-5-(pyridine-2-ylethynyl-6-methyl)phenyl)(4-methoxyphenyl)iodonium 
hexafluorophosphate (50 mg, 0.0839 mmol) was dissolved in a minimal amount(0.5 mL) 
of acetonitrile.  The solution was flowed through a 12 mm diameter column packed to a 
height of 10 cm with Amberlite-IRA 400 ion exchange resin (OTf) in acetonitrile.  
Evaporation of the eluted product yielded a colorless solid that was recrystallized from 
acetone/hexane to yield (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-
methoxyphenyl)iodonium trifluoromethanesulfonate ( 50 mg, 100%). 
1
H NMR (400MHz, CD3CN):  = 8.47 (t, 1 H, J = 1.2 Hz), 8.39 (t, 1 H, J = 1.6 Hz), 8.18 
(d, 1 H  J = 1.2 Hz), 8.07 (dd, 2 H, J1 = 2.4 Hz, J2 = 7.2 Hz), 7.70 (t, 1 H, J = 7.8 Hz), 
7.44 (d, 1 H, J = 7.6 Hz), 7.29 (d,  1 H, J = 7.6 Hz), 7.09 (dd, 2 H, J1 = 2.0 Hz, J2 = 7.2 
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Hz), 3.82 (s, 3 H), 2.51 (s, 3 H); 
13
C (75 MHz, CD3CN):  = 163.70, 159.60, 141.36, 
139.00, 138.24, 137.87, 136.97, 126.70, 125.04, 123.97, 118.38, 115.54, 113.28, 101.66, 
55.82, 23.50, 23.50, 0.72; 
19
F NMR (282 MHz, CD3CN):  = -79.30 (s, 3 F); HR-FAB 
MS: (M-OTf)
+
 451.0288 m/z (calcd for C22H16IN2O, 451.03). 
 
 
Preparation of an analytical standard of 3- Fluoro-5-(6-methylpyridine-2-
ylethynyl)benzonitrile 
Preparation of fluorinated standard was done for HPLC analysis.  6-methyl-2-
ethynylpyridine (100mg, 0.855 mmol) was placed in a storage tube along with 2-bromo-
4-fluorobenzonitile (171 mg, 0.855 mmol) and triethylamine (5 mL).  The reactions 
mixture was degassed and canulated into a storage tube containing Dichloro-
ditriphenylphosphine palladium (II) ( 5 mol%) and CuI ( 5 mol%).  The reaction was 
capped and heated to 80 °C for 18 hrs.  The reaction mixed was removed from heat and 
an aqueous workup was performed with water and EtOAc.  The organic layer was dried 
over sodium sulfate.  Flash chromatography was performed on the reaction mixture, 
product eluted in 5% triethylamine in hexanes.  Product was brown solid.  
Recrystalization was performed with hexanes to yield white crystals. (30%)  
50 
 
1
H(400MHz, CD3CN): = 7.82 (s, 1 H), 7.72 (t, 1 H, J = 7.6 Hz), 7.67 (dd, 1 H, J1 = 1.0 
Hz, J2 = 8.2 Hz,), 7.61 (dd, 1 H, J1 = 1.6 Hz, J2 = 8.2 Hz), 7.46 (d, 1 H, J = 7.6 Hz), 7.29 
(d, 1 H, J = 8 Hz), 2.54 (s, 3 H); 
13
C (75 MHz, CD3CN):  = 163.56, 160.23, 159.36, 
141.24, 136.70, 131.51, 131.47, 126.25, 124.79, 123.65, 123.34, 119.56, 119.23, 116.78, 
114.23; 
19
F (376MHz, CD3CN):  = -112.18 (t, 7.52, 1 F); HR-FAB MS: (M+H)
+ 
 
237.0825 m/z (calcd C15H10N2F, 236.07) 
 
 
3-fluoro-5-(pyridine-2-ylethynyl-6-methyl)benzonitrile 
Triflate precursor (25mg, 0.0427 mmol) was combined with TMAF (3.3mg, 0.0417 
mmol) in acetonitrile-d3.  This solution is to be kept fairly concentrated, entire process is 
to be kept air-free.  Exchange is instantaneous, and acetonitrile is pumped off.  The 
reaction is redissolved in benzene-d6, and filtered with a membrane filter.  The reaction 
mixture is heated to 140 
o
C for 15 minutes.  Product was purified by flash 
chromatography (silica gel, 85:15 hexanes:ethyl acetate eluant).  The solvent was 
removed in vacuo leaving the product as a crystalline white powder (5.9 mg, 60%).     
19
F (376MHz, CD3CN):  = -112.18 (t, 1 F) 
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APPENDIX A.  
Common Abbreviations Used in this Thesis 
PET  Positron Emission Tomography  
mGluR metabotropic glutamate receptor 
K. 2.2.2 Krytofix 2.2.2. 
RCY  decay-corrected radiochemical yield 
PEB  3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile 
CH3CN acetonitrile  
C6H6  benzene  
TMAF  Tetramethyl ammonium fluoride 
MPEB  3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile 
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APPENDIX B 
NMR Spectra 
1. 1H of 2-((trimethylsilyl)ethynyl)pyridine in CDCl3 
2. 13C of  2-((trimethylsilyl)ethynyl)pyridine in CDCl3 
3. 1H of 2-((trimethylsilyl)ethynyl)pyridine in CDCl3 
4. 13C of 2-((trimethylsilyl)ethynyl)pyridine in CDCl3 
5. 1H of 3-bromo-5-(pyridin-2-ylethynyl)benzonitrile in CDCl3 
6. 13C of 3-bromo-5-(pyridin-2-ylethynyl)benzonitrile in CDCl3 
7. 1H of 3-(Pyridin-2-ylethynyl)-5-(tributylstannyl)benzonitrile in CD3CN 
8. 13C of 3-(Pyridin-2-ylethynyl)-5-(tributylstannyl)benzonitrile in CD3CN 
9. 1H of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
 hexafluorophosphate in CD3CN 
10. 13C of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
 hexafluorophosphate in CD3CN 
11. 19F of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
 hexafluorophosphate in CD3CN 
12. 1H of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
 trifluoromethanesulfonate in CD3CN 
13. 13C of (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
 trifluoromethanesulfonate in CD3CN 
14. 19F (3-Cyano-5-(pyridine-2-ylethynyl)phenyl)(4-methoxyphenyl)iodonium 
 trifluoromethanesulfonate in CD3CN 
15. 19F of 3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile in CD3CN 
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16. 1H of  3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile in CD3CN 
17. 13C of  3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile in CD3CN 
18. 19F of  3-Fluoro-5-(pyridine-2-ylethynyl)benzonitrile in CD3CN 
19. 1H of 2-methyl-6-((trimethylsilyl)ethynyl)pyridine in CDCl3 
20. 13C of 2-methyl-6-((trimethylsilyl)ethynyl)pyridine in CDCl3 
21. 1H of 2-methyl-6-((trimethylsilyl)ethynyl)pyridine in CDCl3 
22. 1H of 3-bromo-5-((6-methylpyridin-2-yl)ethynyl)benzonitrile in CDCl3 
23. 13C of 3-bromo-5-((6-methylpyridin-2-yl)ethynyl)benzonitrile in CDCl3 
24. 1H of 3-((6-methylpyridin-2-yl)ethynyl)-5-(tributylstannyl)benzonitrile in CD3CN 
25. 13C of 3-((6-methylpyridin-2-yl)ethynyl)-5-(tributylstannyl)benzonitrile in 
CD3CN 
26. 1H of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-
 methoxyphenyl)iodonium hexafluorophosphate in CD3CN 
27. 13C of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-
 methoxyphenyl)iodonium hexafluorophosphate in CD3CN 
28. 19F of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-
 methoxyphenyl)iodonium hexafluorophosphate in CD3CN 
29. 1H of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-
 methoxyphenyl)iodonium trifluoromethanesulfonate in CD3CN 
30. 13C of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-
 methoxyphenyl)iodonium trifluoromethanesulfonate in CD3CN 
31. 19F of (3-cyano-5-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-
 methoxyphenyl)iodonium trifluoromethanesulfonate in CD3CN 
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32. 19F of 3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile in CD3CN 
33. 1H of 3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile in CD3CN 
34. 13C of 3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile in CD3CN 
35. 19F of 3- Fluoro-5-(6-methylpyridine-2-ylethynyl)benzonitrile in CD3CN 
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